6 results for "Epilepsy"
This study is exploring a medication (currently on the market) for its effectiveness in controlling “grand-mal” seizures in patients with a specific type of epilepsy.
This study evaluates the pharmacokinetic and safety of NRL-1 in epilepsy subjects. Subjects will receive a single intranasal dose of NRL-1 of either 5 mg, 10 mg, 15 mg or 20 mg and will be based on the subject's body weight.
This study allows patients with uncontrolled seizures and a specific type of epilepsy access to an on-market drug to control seizures. This study is currently only available for patients who have enrolled in the SP0982 study.
Medication trial for patients suffering from super-refractory status epilepticus (life-threatening, continuous seizures) that has failed traditional treatment.
The purpose of this study is to evaluate the safety and effectiveness of ATryn in subjects with preterm preeclampsia. This study involves research to assess if ATryn can:
- increase the time the baby stays in the womb
- decrease problems the mother may experience
- improve the health and well-being of the baby
This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as blinatumomab, may block cancer growth in different ways by targeting certain cells. It is not yet known whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia.